Company profile: MBrace Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical oncology solutions, including MBRC-101, an antibody-drug conjugate targeting the EphA5 receptor for solid tumors such as breast and lung cancer; SPARTA, a proprietary platform to identify new cancer targets and accelerate ADC development; and a Phase 1/1b clinical trial of MBRC-101 evaluating safety, tolerability, and preliminary efficacy in advanced metastatic solid tumors.
Products and services
- SPARTA technology: A proprietary platform that identifies new cancer targets and accelerates the development of antibody-drug conjugates for oncology programs
- Phase 1/1b clinical trial of MBRC-101: A Phase 1/1b study to evaluate the safety, tolerability, and preliminary efficacy of MBRC-101 in patients with advanced metastatic solid tumors
- MBRC-101: A receptor-targeted antibody-drug conjugate targeting the EphA5 receptor for the treatment of various solid tumors, including breast and lung cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MBrace Therapeutics
Alaunos Therapeutics
HQ: United States
Website
- Description: Provider of TCR-T cell therapies and supporting platforms for cancer treatment, including non-viral TCR-T therapy for solid tumors, the Sleeping Beauty transposition system for TCR gene transfer, the hunTR discovery engine to identify new TCRs, and a clinical TCR library targeting frequent mutations such as KRAS, TP53, and EGFR, backed by in-house manufacturing for rapid, cost-effective TCR-T production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alaunos Therapeutics company profile →
Scancell
HQ: United Kingdom
Website
- Description: Provider of immunotherapy platforms and therapeutic vaccines for cancer and infectious diseases, including ImmunoBody and Moditope for cancer vaccines, GlyMab for glycan-targeting monoclonal antibodies, AvidiMab to enhance antibody potency and tumor specificity, and melanoma vaccines SCIB1 and iSCIB1+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scancell company profile →
Arch Oncology
HQ: United States
Website
- Description: Provider of venture-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Oncology company profile →
Medannex
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical solutions targeting annexin-A1, notably MDX-124—a humanised monoclonal antibody with potential in treating various cancers and autoimmune diseases—and the ATTAINMENT Phase 1b clinical study evaluating the safety, tolerability, and efficacy of MDX-124 in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medannex company profile →
ISA Pharmaceuticals
HQ: The Netherlands
Website
- Description: Provider of clinical-stage, fully synthetic immunotherapeutics and therapeutic vaccines for cancer and persistent viral infections, built on its Synthetic Long Peptide (SLP®) and AMPLIVANT® platforms; products include ISA101b for HPV16-induced cancers and ISA104 for chronic hepatitis B infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ISA Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MBrace Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MBrace Therapeutics
2.2 - Growth funds investing in similar companies to MBrace Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MBrace Therapeutics
4.2 - Public trading comparable groups for MBrace Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →